Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of gastrointestinal transit modulation on fructose metabolism
NL-OMON58505Recruiting
- Sponsor
- Maastricht University
- Start
- Jul 2026
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Open-label trial of liraglutide and erythromycin in metabolic dysfunction-associated steatotic liver disease (MASLD) and steatosis (2 arms), sponsored by Maastricht University. Started Jul 2026; status: recruiting.
02
Drugs
liraglutideerythromycin
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)steatosis
Beyond the preview
Go deeper on NL-OMON58505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58505.